Please login to the form below
biomarkers
This page shows the latest biomarkers news and features for those working in and with pharma, biotech and healthcare.
Michael J Fox Foundation awards Koneksa second research grant
The grant will be used to evaluate whether digital biomarkers can help to predict the different stages of Parkinson’s disease. ... Predictive digital biomarkers will lead to better diagnosis and hopefully life-saving therapies for patients with PD.”.
Latest news
-
AstraZeneca’s Tezspire recommended for approval in the EU by CHMP
Tezspire is the first and only biologic recommended for EU approval in those with severe asthma with no phenotype or biomarker limitations. ... death. “[Tezspire is] the only biologic recommended for EU approval in severe asthma patients with no
-
Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation
It works by detecting and measuring Alzheimer's disease biomarkers in blood plasma. ... These biomarkers can signal a need for further tests. Roche is the first in-vitro diagnostics manufacturer to be given this designation for a blood-based biomarker
-
NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients
Considering alpelisib [Piqray] involves identifying this specific genomic biomarker via a test, determining who is eligible for this new treatment option and potentially giving them a chance to live longer and
-
EC approves Roche’s Tecentriq for early-stage lung cancer
This milestone reinforces the need for biomarker testing at diagnosis for all people with NSCLC, irrespective of disease stage, to ensure they receive optimal treatment.”.
-
Biogen and Eisai announce FDA submission for early Alzheimer’s treatment
The BLA submission for lecanemab is based on clinical, biomarker and safety data from the proof-of-concept phase 2b trial involving 856 people with early AD.
More from news
Approximately 6 fully matching, plus 351 partially matching documents found.
Latest Intelligence
-
How early-stage clinical research is facilitating the new wave of personalised medicines
as the technology is tested in more conditions and biomarkers. ... with a certain condition and biomarker.
-
Alzheimer’s: the search for a cure
Based on major progress in the development of biomarkers for Alzheimer’s disease – including the visualisation of the proteins tau and amyloid in the patient brain with newly developed tracers for
-
Successful product commercialisation: what can we learn from the rare disease setting?
This is clearly an important factor in a setting where endpoints may be disputed, or biomarkers not validated – but it’s important to ensure an understanding of patients’ needs for all
-
Unlocking the potential of precision medicine in oncology
I am constantly impressed by the tireless endeavours of our biomarker scientists who. ... These tests are designed to detect multiple biomarker changes simultaneously, and efforts are ongoing to understand the changes that occur in circulating tumour
-
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
2. Digital medicine (eg, digital diagnostics and biomarkers, where requirements for regulatory oversight vary).
More from intelligence
Approximately 2 fully matching, plus 55 partially matching documents found.
Latest appointments
-
Ex-BMS exec jumps to Gilead to lead research group
That included the expansion of the company’s biologics and biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.
-
BMS appoints new commercial leader, Davies joins Eisai and more
The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy.
-
Industry appointments
Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
-
Annalisa Jenkins joins biomarker firm PlaqueTec as CEO
2018 launch of the biomarker-based liquid biopsy system (LBS).
-
Paul Stockdale joins Oxford BioDynamics as CFO
A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.
More from appointments
Approximately 0 fully matching, plus 16 partially matching documents found.
Latest from PMHub
-
Artificial Intelligence for Identifying and Monitoring Cognitive Decline
Liam Kaufman, CEO &Co-founder of Winterlight Labs, explores a range of topics related to AI, machine learning, natural language processing, digital biomarkers, and human-computer interactions in healthcare.
-
Leveraging Real-Time Health Data for Proactive, Predictive Care
Alex Gilbert, Head of Digital Medicines Development &Life Sciences Partnerships at Huma, explores virtual &decentralized trials, digital biomarkers, digital-first delivery of care, at-home hospitals, and many other thought-provoking
-
The future of nanomedicine regulation
Nanomedicine is not limited to nanopharmaceuticals but also includes devices, such as lateral flow tests that use gold nanoparticles to detect specific biomarkers or the use of nanofibers as scaffolds for
-
Consumer-driven Healthcare in the Digital Age
Gil Blander, Co-founder &Chief Scientific Officer at InsideTracker, explores consumer-driven healthcare, the use of big data and AI for creating personalized health protocols, the trillion-dollar “longevity economy,” and how approaches like
-
Rare Disease Day – looking to the future with hope
the characterisation of subpopulations), clinical outcome measures and biomarkers, and facilitate the development of mathematical models of disease and innovative clinical trial design.
More from PMHub
Approximately 12 fully matching, plus 22 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
